ACB Stock Overview
Engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aurora Cannabis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.34 |
| 52 Week High | CA$9.35 |
| 52 Week Low | CA$2.84 |
| Beta | 2.7 |
| 11 Month Change | -26.81% |
| 3 Month Change | -33.02% |
| 1 Year Change | -9.19% |
| 33 Year Change | -93.61% |
| 5 Year Change | -98.55% |
| Change since IPO | -88.45% |
Recent News & Updates
Recent updates
Aurora Cannabis: Revving Up To Profitability
Aug 08Aurora launches new cannabis products for adult and medical-use
Oct 17Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes
Oct 07Aurora Cannabis Q4 2022 Earnings Preview
Sep 19Aurora Cannabis: Don't Let Your Money Go Up In Smoke
Aug 25Why Did Aurora Cannabis Stock Crash In May; Can It Recover?
Jun 13Recent Developments Do Not Change Our Stance On Aurora Cannabis
May 13Aurora Cannabis: A Train Wreck Desperate For Help
May 05Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way
Feb 17Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?
Dec 17Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks
Oct 11Aurora Cannabis: Investors Should Have No Confidence In This Company
Sep 28Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity
Sep 16Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry
Jun 05Aurora Cannabis: Extreme Downside Case Averted
Feb 02Shareholder Returns
| ACB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.3% | 1.6% | 2.2% |
| 1Y | -9.2% | 9.9% | 31.6% |
Return vs Industry: ACB underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: ACB underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| ACB volatility | |
|---|---|
| ACB Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACB's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1,073 | Miguel Martin | www.auroramj.com |
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; supplies propagated vegetables and ornamental plants; and distributes and sells hemp-derived cannabidiol (CBD) products.
Aurora Cannabis Inc. Fundamentals Summary
| ACB fundamental statistics | |
|---|---|
| Market cap | US$237.38m |
| Earnings (TTM) | -US$21.29m |
| Revenue (TTM) | US$212.48m |
1.1x
P/S Ratio-11.1x
P/E RatioIs ACB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACB income statement (TTM) | |
|---|---|
| Revenue | CA$296.99m |
| Cost of Revenue | CA$139.24m |
| Gross Profit | CA$157.75m |
| Other Expenses | CA$187.52m |
| Earnings | -CA$29.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 53.12% |
| Net Profit Margin | -10.02% |
| Debt/Equity Ratio | 9.9% |
How did ACB perform over the long term?
See historical performance and comparison